Juglans Nigra

Picotamide is a platelet aggregation inhibitor. It works as a thromboxane synthase inhibitor and a thromboxane receptor inhibitor, the latter by modifying cellular responses to activation of the thromboxane receptor.^[1] Picotamide is licensed in Italy for the treatment of clinical arterial thrombosis and peripheral artery disease.^[2]

References

^ Ratti S, Quarato P, Casagrande C, Fumagalli R, Corsini A (August 1998). "Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes". European Journal of Pharmacology. 355 (1): 77–83. doi:10.1016/S0014-2999(98)00467-1. PMID 9754941.
^ Capra V, Bäck M, Angiolillo DJ, Cattaneo M, Sakariassen KS (February 2014). "Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation". Journal of Thrombosis and Haemostasis. 12 (2): 126–137. doi:10.1111/jth.12472. PMID 24298905.